Panels and models for accurate prediction of tumor mutation burden in tumor samples
Abstract Immune checkpoint blockade (ICB) is becoming standard-of-care in many types of human malignancies, but patient selection is still imperfect. Tumor mutation burden (TMB) is being evaluated as a biomarker for ICB in clinical trials, but most of the sequencing panels used to estimate it are in...
Guardado en:
Autores principales: | Elizabeth Martínez-Pérez, Miguel Angel Molina-Vila, Cristina Marino-Buslje |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1b76c4e637d44f018df09d860ec13ed7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups
por: Yan W. Asmann, et al.
Publicado: (2021) -
Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer
por: Hongsik Kim MD, et al.
Publicado: (2021) -
Exploration of the Tumor Mutational Burden
as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer
por: Licheng Wang MM, et al.
Publicado: (2021) -
Distinct mutational profile and immune microenvironment in microsatellite-unstable and POLE-mutated tumors
por: Hee Sang Hwang, et al.
Publicado: (2021) -
Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer
por: Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted Therapy, et al.
Publicado: (2021)